GUCY1B3 Antibody

What is GUCY1B3 and why is it an important research target?

GUCY1B3 (also known as Guanylyl Cyclase beta 1, GC-S-beta-1, GUCB3, GC-SB3, GUC1B3, or GUCSB3) functions as a key component of the guanylyl cyclase enzyme complex responsible for converting GTP to cGMP. This pathway is critical in various physiological processes including vascular homeostasis, neurotransmission, and cellular growth. Dysregulation of cGMP signaling has been implicated in cardiovascular disorders, neurological conditions, and cancer, making GUCY1B3 an important research target for understanding disease mechanisms and identifying potential therapeutic targets .

What types of GUCY1B3 antibodies are available for research applications?

Multiple validated antibodies targeting GUCY1B3 are available from research suppliers:

The selection should be based on specific experimental requirements, including application type, species reactivity, and validated performance in relevant tissue or cell types .

How do the molecular properties of GUCY1B3 affect antibody selection and experimental design?

GUCY1B3 has a calculated molecular weight of 71 kDa, but is observed at 67-71 kDa in experimental conditions due to post-translational modifications. When designing experiments, researchers should consider:

• Antibody epitope location (N-terminal vs C-terminal)

• Potential splice variants or post-translational modifications

• Protein-protein interactions that might mask epitopes

• Sample preparation methods that could affect epitope accessibility

For example, antibody CAB3687 targets a sequence within amino acids 1-100 of human GUCY1B3 (UniProt: Q02153), making it suitable for detecting the full-length protein but potentially less effective for detecting certain fragments or modified forms .

What are the optimal conditions for Western blot detection of GUCY1B3?

For optimal Western blot detection of GUCY1B3:

Methodological considerations:

• Use fresh tissue lysates when possible

• Include reducing agents in sample buffer

• Run adequate molecular weight markers to confirm target band

• Consider gel percentage (8-10% typically optimal for 70kDa proteins)

• Include positive controls from validated tissues

• Block with 5% non-fat milk or BSA in TBST

What approaches should be used for immunohistochemical detection of GUCY1B3 in tissue sections?

For successful immunohistochemical detection:

Methodological recommendations:

• Optimization of antigen retrieval is critical (test both citrate and TE buffer conditions)

• Use positive control tissues (mouse brain or human lung cancer)

• Include negative controls (primary antibody omission and isotype controls)

• Consider detection system sensitivity (avidin-biotin vs polymer-based)

• Counterstain appropriately to visualize tissue architecture

• Evaluate signal specificity through peptide blocking or knockout validation

How can GUCY1B3 antibodies be effectively used in immunofluorescence and immunocytochemistry?

For optimal immunofluorescence/immunocytochemistry results:

Methodological advice:

• Optimize fixation conditions (paraformaldehyde vs methanol)

• Test permeabilization reagents (0.1-0.5% Triton X-100 or 0.1% saponin)

• Include appropriate blocking steps (normal serum matching secondary antibody species)

• Consider signal amplification for low abundance targets

• Use counter-staining with DAPI for nuclear visualization

• Employ confocal microscopy for detailed subcellular localization

• Validate with siRNA knockdown controls when possible

How can researchers address common issues with GUCY1B3 antibody specificity?

To ensure GUCY1B3 antibody specificity:

• Validate with multiple antibodies targeting different epitopes

• Include knockout/knockdown controls:

  • Published knockout validation is available for some antibodies

• Perform peptide competition assays

• Test across multiple applications (e.g., if a band appears in WB, confirm by IHC)

• Compare observed molecular weight with theoretical weight

• Evaluate tissue/cell expression patterns against known GUCY1B3 distribution

• Consider cross-reactivity with related proteins (especially other guanylyl cyclase family members)

Methodological approach for peptide competition:

• Pre-incubate antibody with 5-10x molar excess of immunizing peptide

• Run parallel samples with blocked and unblocked antibody

• True specific signals should be eliminated by peptide competition

What strategies can optimize immunoprecipitation of GUCY1B3 for protein interaction studies?

For successful GUCY1B3 immunoprecipitation:

Methodological considerations:

• Lysis buffer optimization:

  • Test different detergents (NP-40, CHAPS, Triton X-100)

  • Include protease/phosphatase inhibitors

  • Adjust salt concentration to maintain interactions

• Pre-clearing with protein A/G beads to reduce background

• Antibody binding conditions:

  • Overnight incubation at 4°C with gentle rotation

  • Titrate antibody amount to minimize non-specific binding

• Washing stringency balance:

  • Sufficient to remove non-specific interactions

  • Gentle enough to maintain specific interactions

• Elution methods:

  • Gentle (native conditions): competitive peptide elution

  • Harsh (denaturing): SDS-containing buffer at 95°C

• Control IPs with isotype-matched irrelevant antibodies

How can ChIP-seq be optimized for studying GUCY1B3 chromatin interactions?

Based on published ChIP-seq analysis of GUCY1B3 binding to chromatin DNA (GEO accession: GSE83419) , researchers should consider:

• Crosslinking optimization:

  • Test formaldehyde concentrations (0.5-1.5%)

  • Evaluate crosslinking times (5-20 minutes)

  • Consider dual crosslinkers for improved capture

• Sonication parameters:

  • Optimize to achieve 200-500bp DNA fragments

  • Verify fragmentation efficiency by gel electrophoresis

• Antibody selection and validation:

  • Confirm ChIP-grade quality

  • Test antibody performance in preliminary ChIP-qPCR

  • Validate with known binding sites before whole-genome analysis

• Bioinformatic analysis considerations:

  • Peak calling algorithms

  • Integration with transcriptomic data

  • Motif analysis for binding site consensus

  • Pathway enrichment of target genes

• Validation approaches:

  • ChIP-qPCR of selected targets

  • Reporter assays for functional validation

  • CRISPR-mediated disruption of binding sites

What methods can be used to study the role of GUCY1B3 in disease models and potential therapeutic targeting?

Advanced methodological approaches include:

• Tissue-specific expression analysis:

  • Compare GUCY1B3 expression in normal vs. disease tissue

  • Use validated antibodies for IHC (dilution 1:50-1:500) on tissue microarrays

  • Correlate expression with clinical parameters

• Functional studies:

  • siRNA/shRNA knockdown approaches

  • CRISPR/Cas9 genome editing

  • Small molecule modulators of guanylyl cyclase activity

  • Assessment of downstream cGMP signaling

• In vivo models:

  • Conditional knockout mouse models

  • Disease-specific transgenic models

  • Antibody-based detection in model tissues:

    • Brain (1:50-1:200 dilution)

    • Lung (1:50-1:200 dilution)

    • Heart (1:50-1:200 dilution)

• Therapeutic targeting approaches:

  • Analysis of cGMP pathway modulators

  • Identification of protein-protein interaction targets

  • Development of allosteric modulators

  • Evaluation of pathway cross-talk with NO signaling

How can GUCY1B3 antibodies be used to investigate protein-protein interactions in signaling complexes?

Methodological approaches for studying GUCY1B3 protein interactions:

• Co-immunoprecipitation (Co-IP):

  • Use 0.5-4.0 μg antibody per 1.0-3.0 mg total protein

  • Extract under non-denaturing conditions

  • Include appropriate controls (IgG, reverse Co-IP)

  • Analysis by Western blot or mass spectrometry

• Proximity ligation assay (PLA):

  • Allows in situ detection of protein interactions

  • Requires antibodies from different species or isotypes

  • Provides spatial context for interactions

  • Use antibody dilutions of 1:50-1:100

• FRET/BRET analysis:

  • Fusion protein construction

  • Live cell imaging

  • Quantification of energy transfer efficiency

• Bimolecular fluorescence complementation (BiFC):

  • Split fluorescent protein approach

  • Visualization of interaction sites

  • Irreversible complex formation for stable detection

• Mass spectrometry-based interactomics:

  • Immunoprecipitation using validated antibodies

  • Label-free or isotope-labeled quantification

  • Network analysis of interaction partners

  • Functional classification of interactors

How can multi-omics approaches integrate GUCY1B3 antibody-based data with other molecular profiles?

Integrated methodological framework:

• Antibody-based proteomics:

  • Immunohistochemistry on tissue microarrays

  • Reverse phase protein arrays

  • Single-cell protein analysis

• Integration strategies:

  • Correlation of protein expression with transcriptomic data

  • Pathway analysis incorporating ChIP-seq binding data

  • Network biology approaches linking protein interactions with metabolomic changes

  • Machine learning algorithms for pattern recognition across data types

• Validation approaches:

  • Perturbation studies with knockdown/overexpression

  • Functional assays measuring cGMP pathway activity

  • In vivo modeling of key findings

• Computational resources:

  • Pathway databases

  • Protein interaction networks

  • Systems biology modeling tools

What considerations are important when studying post-translational modifications of GUCY1B3?

Methodological approaches for studying GUCY1B3 post-translational modifications:

• Phosphorylation analysis:

  • Phospho-specific antibodies (if available)

  • Phosphatase treatment controls

  • PhosTag gels for mobility shift detection

  • Mass spectrometry for site identification

• Sample preparation:

  • Rapid extraction in presence of phosphatase inhibitors

  • Optimization of lysis buffers to maintain modifications

  • Subcellular fractionation to enrich modified pools

• Validation strategies:

  • Site-directed mutagenesis of modified residues

  • Pharmacological modulation of modifying enzymes

  • Correlation with functional readouts (cGMP production)

• Advanced mass spectrometry approaches:

  • Targeted analysis of known sites

  • Discovery mode for novel modifications

  • Quantification of modification stoichiometry

  • Correlation with enzyme activity

The observed molecular weight range (67-71 kDa) compared to the calculated weight (71 kDa) suggests possible post-translational modifications that researchers should consider when designing experiments and interpreting results .